Top Markets
#1 DogBull DogBull +69.44%
#2 Siren Siren +31.70%
#3 OriginTrail OriginTrail +18.07%
#4 MarsCoin MarsCoin +9.72%
#5 Verus Coin Verus Coin +7.42%
#6 Falcon Finance Falcon Finance +6.32%
#7 RedStone RedStone +6.11%
#8 PulseChain PulseChain +6.04%
#9 Xphere Xphere +5.90%
#10 Concordium Concordium +5.69%
Coin of the day
DogBull DogBull
Setări
Limbă
ROMâNă
Monedă
USD
Temă
RaQualia Pharma Inc. RaQualia Pharma Inc.

RaQualia Pharma Inc.

4579
Rang în acțiuni #22339
RaQualia Pharma Inc., established in 2008 and based in Nagoya, Japan, is a... RaQualia Pharma Inc., established in 2008 and based in Nagoya, Japan, is a pharmaceutical company dedicated to the global research and development of innovative drug compounds. Its human therapeutic pipeline features several key candidates. Tegoprazan, designed to treat gastroesophageal reflux disease (GERD), is currently undergoing Phase 1 clinical trials in the United States. Grapiprant is in Phase II development in the U.S. and Phase I in China for pain management; it is also being investigated in Phase I studies in both the U.S. and China for its potential in cancer therapy. Beyond human medicines, RaQualia Pharma develops a range of veterinary products. These include grapiprant for managing osteoarthritis in dogs, a ghrelin receptor agonist aimed at addressing cancer-related anorexia/cachexia syndrome and constipation stemming from spinal cord injury, and ELURA, a medication for combating weight loss in cats suffering from chronic kidney disease. The company's extensive R&D pipeline also covers various other therapeutic areas. This includes a TRPM8 blocker for neuropathic pain, a motilin receptor agonist targeting gastrointestinal motility disorders such as gastroparesis, functional dyspepsia, and post-operative ileus, and a potassium-competitive acid blocker for GERD, which has successfully concluded Phase 1 clinical trials. Further early-stage developments encompass a 5-HT4 partial agonist for gastroparesis, functional dyspepsia, and chronic constipation; a 5-HT2B antagonist for irritable bowel syndrome with diarrhea; EP4 antagonists for canine pain management and, in separate Phase I trials, for cancer and general pain indications; a serotonin 5-HT2A and dopamine D2 receptor blocker for schizophrenia; a Cyclooxygenase-2 inhibitor (Phase I for pain); a CB2 agonist; a selective sodium channel blocker; a P2X7 receptor antagonist (Phase I for neuropathic pain); and a retinoic acid receptor alpha agonist. To further its research and development initiatives, RaQualia maintains strategic partnerships with Interprotein Corporation, ASKA Pharmaceutical Co., Ltd., and Epigeneron, Inc.
Preț acțiune
$3.69
Ultima sincronizare: 2026-08-21
Capitalizare de piață
$90.16M
Schimbare (1 zi)
-3.58%
Schimbare (1 an)
0.33%
Țară
JP
Tranzacționează RaQualia Pharma Inc. (4579)

Categorie

Healthcare
Istoric al prețului acțiunii pentru RaQualia Pharma Inc. (4579)
Cel mai mare preț de închidere: $3.51 pe 2026-08-01

Cel mai mic preț de închidere: $16.15 pe 2011-07-01
Istoric al prețului acțiunii pentru RaQualia Pharma Inc. din 2011 până în 2026
Evoluția anuală a prețului acțiunii
An Performanță
2026 (TTM) -35.31%
2025 181.95%
2024 -47.00%
2023 -48.76%
2022 11.44%
2021 -11.84%
2020 -15.83%
2019 25.81%
2018 -23.34%
2017 253.86%
2016 14.10%
2015 -21.95%
2014 -41.97%
2013 51.35%
2012 -23.72%
2011 0.00%
Prețul acțiunii pentru companii similare sau concurente
Companie Preț acțiune Variație 1an% Țara
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $547.71 38.62%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $1.04K 58.06%
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $145.75 437.43%
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $118.70 -15.60%
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 $770.19 8.98%
CH